Gilead Sciences announced positive results from a phase 2 study evaluating its investigational, once-daily oral α4β7 integrin inhibitor, emvistegrast, in adults with moderately to severely active ulcerative colitis.
At week 12 in the phase 2 SWIFT dose-ranging study, the primary endpoint of clinical response was achieved by 66% (33/59) of participants receiving emvistegrast 200 mg compared with 37% (22/60) of participants receiving placebo. Clinical remission was achieved by 31% (18/59) and 8% (5/60) of participants receiving emvistegrast 200 mg or placebo, respectively.
Ulcerative colitis is a chronic, relapsing inflammatory bowel disease that can substantially affect quality of life and long-term health outcomes. Despite the availability of multiple advanced therapies, many people living with UC do not achieve sustained disease control, underscoring the need for additional treatment approaches. Emvistegrast is a once-daily oral therapy designed to selectively inhibit the α4β7 pathway, a clinically validated target in inflammatory bowel disease.